McKenney James M
National Clinical Research, Inc., and School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA.
Clin Cardiol. 2003 Apr;26(4 Suppl 3):III32-8. doi: 10.1002/clc.4960261507.
Considerable effort has been devoted to improving the pharmacologic characteristics and clinical effects of statins. Desirable pharmacologic properties include potent inhibition of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, selectivity of uptake in hepatocytes, low systemic bioavailability to reduce systemic adverse effects, prolonged elimination half-life, and no or minimal hepatic metabolism to avoid drug-drug interactions. The desirable effects on lipid variables would include increased effectiveness in reducing levels of low-density lipoprotein cholesterol and other atherogenic lipoproteins and measurable beneficial effects on high-density lipoprotein cholesterol levels. As a product of the ongoing efforts regarding statin pharmacology, the new statin rosuvastatin exhibits significant improvements in several of these characteristics.
人们已付出相当大的努力来改善他汀类药物的药理学特性和临床效果。理想的药理学特性包括对羟甲基戊二酰辅酶A(HMG-CoA)还原酶的强效抑制、在肝细胞中的摄取选择性、降低全身不良反应的低全身生物利用度、延长消除半衰期以及无或极少的肝脏代谢以避免药物相互作用。对脂质变量的理想作用包括在降低低密度脂蛋白胆固醇和其他致动脉粥样硬化脂蛋白水平方面提高有效性,以及对高密度脂蛋白胆固醇水平产生可测量的有益作用。作为他汀类药物药理学持续研究的成果,新型他汀类药物瑞舒伐他汀在其中几个特性方面有显著改善。